# Regulus Therapeutics Inc. (RGLS)

Source: https://www.quantisnow.com/company/RGLS
Generated: 2026-11-09T10:43:11.472Z

- Ticker: RGLS
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2012
- Website: regulusrx.com

## About

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase 1 development for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 glioblastoma multiforme program; and Hepatitis B virus, non-alcoholic steatohepatitis, and cell therapies programs. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

## Latest RGLS news and filings

- 2025-07-07 10:01 UTC [SEC Form 15-12G filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-regulus-therapeutics-inc-6111929)
- 2025-07-02 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-regulus-therapeutics-inc-6106969)
- 2025-07-02 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-regulus-therapeutics-inc-6106965)
- 2025-07-02 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-regulus-therapeutics-inc-6106963)
- 2025-07-02 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-regulus-therapeutics-inc-6106961)
- 2025-07-02 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-regulus-therapeutics-inc-6106958)
- 2025-07-02 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-regulus-therapeutics-inc-6106954)
- 2025-07-02 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-regulus-therapeutics-inc-6106951)
- 2025-07-02 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-regulus-therapeutics-inc-6106950)
- 2025-06-27 21:12 UTC [SEC Form 4] [Director Rastetter William H returned 57,292 shares to the company (SEC Form 4)](https://www.quantisnow.com/insight/director-rastetter-william-h-returned-57292-shares-to-the-company-6102263)
- 2025-06-27 21:12 UTC [SEC Form 4] [Director Witz Pascale returned 67,233 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-witz-pascale-returned-67233-shares-to-the-company-closing-6102262)
- 2025-06-27 21:11 UTC [SEC Form 4] [Director Papadopoulos Stelios returned 64,635 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-papadopoulos-stelios-returned-64635-shares-to-the-company-closing-6102260)
- 2025-06-27 21:09 UTC [SEC Form 4] [Director Rosen Hugh returned 57,292 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-rosen-hugh-returned-57292-shares-to-the-company-closing-6102252)
- 2025-06-27 21:06 UTC [SEC Form 4] [President & Head of R & D Klassen Preston returned 115,555 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/president-head-of-r-d-klassen-preston-returned-115555-shares-6102236)
- 2025-06-27 21:06 UTC [SEC Form 4] [Sr. VP & General Counsel Aker Christopher Ray returned 83,125 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/sr-vp-general-counsel-aker-christopher-ray-returned-83125-shares-6102235)
- 2025-06-27 21:05 UTC [SEC Form 4] [Chief Executive Officer Hagan Joseph P returned 571,558 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-hagan-joseph-p-returned-571558-shares-to-6102229)
- 2025-06-27 21:03 UTC [SEC Form 4] [Director Baltimore David returned 114,584 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-baltimore-david-returned-114584-shares-to-the-company-closing-6102219)
- 2025-06-27 21:02 UTC [SEC Form 4] [Director Nunn Jason Raleigh returned 62,500 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-nunn-jason-raleigh-returned-62500-shares-to-the-company-6102215)
- 2025-06-27 21:01 UTC [SEC Form 4] [Director Huang Alice Shih-Hou returned 114,584 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-huang-alice-shih-hou-returned-114584-shares-to-the-company-6102213)
- 2025-06-27 21:00 UTC [SEC Form 4] [Director Collier Kathryn J returned 75,565 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-collier-kathryn-j-returned-75565-shares-to-the-company-6102185)
- 2025-06-27 20:58 UTC [SEC Form 4] [Chief Financial Officer Calsada Crispina returned 140,228 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-calsada-crispina-returned-140228-shares-to-the-6102172)
- 2025-06-25 13:34 UTC [SEC Form POS AM filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-regulus-therapeutics-inc-6098597)
- 2025-06-25 13:33 UTC [SEC Form POS AM filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-regulus-therapeutics-inc-6098596)
- 2025-06-25 13:32 UTC [SEC Form POS AM filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-regulus-therapeutics-inc-6098595)
- 2025-06-25 13:31 UTC [SEC Form POS AM filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-regulus-therapeutics-inc-6098593)
- 2025-06-25 13:31 UTC [SEC Form POS AM filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-regulus-therapeutics-inc-6098592)
- 2025-06-25 13:30 UTC [SEC Form POS AM filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-regulus-therapeutics-inc-6098591)
- 2025-06-25 13:30 UTC [SEC Form POS AM filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-regulus-therapeutics-inc-6098590)
- 2025-06-25 13:30 UTC [SEC Form POS AM filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-regulus-therapeutics-inc-6098589)
- 2025-06-25 13:28 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-regulus-therapeutics-inc-6098578)
- 2025-06-25 13:26 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-regulus-therapeutics-inc-6098573)
- 2025-06-25 13:25 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-regulus-therapeutics-inc-6098572)
- 2025-06-25 13:25 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-regulus-therapeutics-inc-6098571)
- 2025-06-25 13:24 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-regulus-therapeutics-inc-6098570)
- 2025-06-25 13:24 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-regulus-therapeutics-inc-6098569)
- 2025-06-25 13:24 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-regulus-therapeutics-inc-6098568)
- 2025-06-25 13:24 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-regulus-therapeutics-inc-6098565)
- 2025-06-25 13:21 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-regulus-therapeutics-inc-6098560)
- 2025-06-25 13:21 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-regulus-therapeutics-inc-6098559)
- 2025-06-25 13:20 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Regulus Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-regulus-therapeutics-inc-6098556)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/RGLS
- Earnings history: https://www.quantisnow.com/earnings/RGLS
- Dividend history: https://www.quantisnow.com/dividends/RGLS
- Insider transactions: https://www.quantisnow.com/insiders/RGLS
- Options chain: https://www.quantisnow.com/options/RGLS
- SEC 8-K filings only: https://www.quantisnow.com/company/RGLS/8-k
- RSS and alerts for RGLS: https://www.quantisnow.com/docs/rss-feeds.md